The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.

Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.

New data with pasritamig plus docetaxel support a recent pivotal start.

An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.

The first fruit of a long-standing deal with Roche enters phase 1 in March.

But biomarker enrichment and toxicity remain key for FX-909.